Alirocumab and Reverse Cholesterol Transport

Completed · Phase 1 · Has a placebo group

Conditions studied: Atherosclerosis, Coronary Heart Disease

In brief

Alirocumab is an injectable treatment for elevated blood cholesterol. The hypothesis of this study is that it also increases cholesterol excretion from the body into the stool, a process sometimes called reverse cholesterol transport. A cholesterol metabolic study will be done before and after 6 weeks of alirocumab treatment. If alirocumab increases reverse cholesterol transport, it is possible that this action provides additional protection from cardiovascular disease.

Key facts

Study ID

NCT03014830

Run by

Washington University School of Medicine

People needed

28

Starts

2017-06-01

Expected to finish

2018-07-30

Last updated by the study team

2018-11-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy or with stable medical or surgical illnesses
• LDL>100 mg/dl.

You may not qualify if…

• Triglycerides>250
• Taking drugs affecting lipid metabolism
• Elevated liver function tests
• Diabetes mellitus
• A1c 6.5% or greater
• Pregnant
• Breastfeeding
• Desire for conception in either sex.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.